Ligand Pharmaceuticals (LGND) Competitors $165.75 -1.31 (-0.78%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$165.78 +0.03 (+0.02%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LGND vs. ADMA, ANIP, BMRN, EXAS, EXEL, IONS, MDGL, HALO, RGEN, and ALKSShould you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Repligen (RGEN), and Alkermes (ALKS). These companies are all part of the "medical" sector. Ligand Pharmaceuticals vs. Its Competitors ADMA Biologics ANI Pharmaceuticals BioMarin Pharmaceutical Exact Sciences Exelixis Ionis Pharmaceuticals Madrigal Pharmaceuticals Halozyme Therapeutics Repligen Alkermes Ligand Pharmaceuticals (NASDAQ:LGND) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment. Which has higher earnings and valuation, LGND or ADMA? ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$167.13M19.44-$4.03M-$4.00-41.44ADMA Biologics$426.45M9.01$197.67M$0.8618.73 Does the media refer more to LGND or ADMA? In the previous week, Ligand Pharmaceuticals had 2 more articles in the media than ADMA Biologics. MarketBeat recorded 5 mentions for Ligand Pharmaceuticals and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.48 beat Ligand Pharmaceuticals' score of 1.22 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, LGND or ADMA? Ligand Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Is LGND or ADMA more profitable? ADMA Biologics has a net margin of 44.06% compared to Ligand Pharmaceuticals' net margin of -40.44%. ADMA Biologics' return on equity of 41.01% beat Ligand Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals-40.44% -9.21% -8.09% ADMA Biologics 44.06%41.01%28.47% Do institutionals and insiders have more ownership in LGND or ADMA? 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate LGND or ADMA? Ligand Pharmaceuticals presently has a consensus price target of $176.50, indicating a potential upside of 6.49%. ADMA Biologics has a consensus price target of $27.67, indicating a potential upside of 71.74%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryADMA Biologics beats Ligand Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGND vs. The Competition Export to ExcelMetricLigand PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.27B$3.20B$5.87B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-41.4421.1774.5225.93Price / Sales19.44480.02549.78198.13Price / Cash103.9746.6837.5660.44Price / Book3.779.6112.166.29Net Income-$4.03M-$53.29M$3.28B$270.77M7 Day Performance-0.60%0.28%0.87%3.88%1 Month Performance6.24%5.73%4.96%4.88%1 Year Performance58.20%10.52%60.74%26.01% Ligand Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGNDLigand Pharmaceuticals4.2298 of 5 stars$165.75-0.8%$176.50+6.5%+62.3%$3.27B$167.13M-41.4480Short Interest ↑ADMAADMA Biologics3.713 of 5 stars$16.99+0.4%$27.67+62.9%-8.7%$4.05B$426.45M19.72530Positive NewsANIPANI Pharmaceuticals4.0413 of 5 stars$95.05-1.0%$84.75-10.8%+74.0%$2.06B$614.38M-123.44600Positive NewsBMRNBioMarin Pharmaceutical4.9429 of 5 stars$57.67+1.6%$93.43+62.0%-35.9%$11.07B$2.85B17.103,040Positive NewsAnalyst UpgradeShort Interest ↑EXASExact Sciences4.8027 of 5 stars$53.65+4.4%$67.05+25.0%-20.0%$10.16B$2.76B-9.887,000Trending NewsAnalyst ForecastShort Interest ↓Analyst RevisionEXELExelixis4.7055 of 5 stars$37.52+0.4%$44.06+17.4%+48.8%$10.11B$2.17B18.051,147IONSIonis Pharmaceuticals3.6813 of 5 stars$61.75+4.0%$67.88+9.9%+54.0%$9.83B$705M-33.531,069Insider TradeMDGLMadrigal Pharmaceuticals4.308 of 5 stars$435.00+0.9%$471.13+8.3%+84.1%$9.66B$180.13M-33.8590Positive NewsAnalyst ForecastInsider TradeHALOHalozyme Therapeutics4.5675 of 5 stars$73.98+0.8%$67.11-9.3%+27.0%$8.65B$1.02B16.92390Positive NewsInsider TradeRGENRepligen4.8927 of 5 stars$124.38+3.1%$169.55+36.3%-20.0%$7.00B$634.44M-497.481,778Positive NewsAnalyst ForecastALKSAlkermes4.5571 of 5 stars$29.69+2.7%$41.31+39.1%+1.5%$4.90B$1.56B14.271,800Trending NewsAnalyst Forecast Related Companies and Tools Related Companies ADMA Competitors ANIP Competitors BMRN Competitors EXAS Competitors EXEL Competitors IONS Competitors MDGL Competitors HALO Competitors RGEN Competitors ALKS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LGND) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LGND Stock Alerts